Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has issued an announcement.
Qyuns Therapeutics Co., Ltd. announced that its long-acting bispecific antibody, QX027N, has received clinical trial approvals for treating asthma and atopic dermatitis, marking a significant milestone in its bispecific antibody pipeline. This development is part of the company’s strategy to advance innovative therapies for respiratory and dermatological diseases, aiming to meet the unmet clinical needs of millions of patients worldwide.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on developing innovative therapies, particularly bispecific antibodies, to address autoimmune and allergic diseases such as asthma and atopic dermatitis.
Average Trading Volume: 948,117
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.31B
For detailed information about 2509 stock, go to TipRanks’ Stock Analysis page.